Core Insights - NeOnc Technologies Holdings, Inc. is set to be featured on "Health Uncensored" hosted by Dr. Drew Pinsky, airing on September 25, 2025, which will provide significant national exposure to the company's innovative therapies for CNS cancers [1][10] - The episode will include discussions on NeOnc's NEO™ platform technology, which aims to overcome the Blood-Brain Barrier, and a patient testimonial highlighting the potential impact of NeOnc's drug candidates [2][3] Company Overview - NeOnc Technologies is a clinical-stage biotechnology company focused on developing therapies for central nervous system cancers, particularly malignant gliomas, utilizing its proprietary NEO™ drug development platform [6] - The company has two lead drug candidates, NEO100™ and NEO212™, currently in Phase II and Phase I clinical trials, respectively, both advancing under FDA Fast-Track status [4][6] Recent Developments - NeOnc has secured a $50 million strategic partnership with Quazar Investment to launch a clinical trials platform in the GCC & MENA regions, enhancing its global presence [12] - The company received FDA authorization to proceed with the Phase II clinical trial of NEO212, a first-in-class oral chemotherapy candidate for brain cancer [12] - NeOnc is nearing full enrollment for its NEO100-01 Phase 2a trial, with top-line data expected in early 2026, and the final patient cohort in the NEO212 Phase I trial is on track for completion in 2025 [12] - The company has been added to the Russell Microcap® Index, increasing visibility among institutional investors [12] - NeOnc received $2.5 million in non-dilutive grants from the NIH to advance its NEO212 program, indicating strong external validation of its scientific approach [12]